James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, outlines the benefits and challenges of transferring ophthalmic care to outpatient facilities.
Transitioning to an outpatient model provides opportunities for savings and efficiency, said James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma.
Transcript
As ophthalmology has evolved into an outpatient specialty over the past few decades, what challenges have come along with this transition?
I wouldn't look at it so much as challenges, as much as the incredible opportunities for cost savings, for efficiency, and for just making it a more patient-friendly environment. I think it's been a tremendous advance. I've seen very few downsides, although there is one small one with trauma which we could go into. Ophthalmologists, in general, have shied away from caring for trauma. It's disruptive to your practice to have a patient come in who needs immediate care, especially if it's complex. The skill set involved is specialized, and it's not something you want to do once every 2 years. When doctors were hospital-based, it was a little bit more, it'd be more common in their practice to encounter this. The trend toward being in private office groups and in surgery centers has sort of put a lot of eye doctors out of touch with trauma care.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More